Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5Y94

Crystal Structure Analysis of the BRD4

Summary for 5Y94
Entry DOI10.2210/pdb5y94/pdb
DescriptorBromodomain-containing protein 4, 5-bromanyl-2-methoxy-N-[3-methyl-6-(methylamino)-1,2-benzoxazol-5-yl]benzenesulfonamide, NITRATE ION, ... (6 entities in total)
Functional Keywordsbrd4(1), bromodomain, transcription
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight17432.71
Authors
Xu, Y.,Zhang, Y.,Song, M.,Wang, C. (deposition date: 2017-08-22, release date: 2018-06-13, Last modification date: 2024-03-27)
Primary citationZhang, M.,Zhang, Y.,Song, M.,Xue, X.,Wang, J.,Wang, C.,Zhang, C.,Li, C.,Xiang, Q.,Zou, L.,Wu, X.,Wu, C.,Dong, B.,Xue, W.,Zhou, Y.,Chen, H.,Wu, D.,Ding, K.,Xu, Y.
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC)
J. Med. Chem., 61:3037-3058, 2018
Cited by
PubMed Abstract: The bromodomain and extra-terminal (BET) family proteins have gained increasing interest as drug targets for treatment of castration-resistant prostate cancer (CRPC). Here, we describe the design, optimization, and evaluation of benzo[ d]isoxazole-containing compounds as potent BET bromodomain inhibitors. Cocrystal structures of the representative inhibitors in complex with BRD4(1) provided solid structural basis for compound optimization. The two most potent compounds, 6i (Y06036) and 7m (Y06137), bound to the BRD4(1) bromodomain with K values of 82 and 81 nM, respectively. They also exhibited high selectivity over other non-BET subfamily members. The compounds potently inhibited cell growth, colony formation, and the expression of AR, AR regulated genes, and MYC in prostate cancer cell lines. Compounds 6i and 7m also demonstrated therapeutic effects in a C4-2B CRPC xenograft tumor model in mice. These potent and selective BET inhibitors represent a new class of compounds for the development of potential therapeutics against CRPC.
PubMed: 29566488
DOI: 10.1021/acs.jmedchem.8b00103
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon